Immunomodulation Mediated by Anti-angiogenic Therapy Improves CD8 T Cell Immunity Against Experimental Glioma

Glioblastoma (GBM) is a lethal cancer of the central nervous system with a median survival rate of 15 months with treatment. Thus, there is a critical need to develop novel therapies for GBM. Immunotherapy is emerging as a promising therapeutic strategy. However, current therapies for GBM, in partic...

Descripción completa

Detalles Bibliográficos
Autores principales: Malo, Courtney S., Khadka, Roman H., Ayasoufi, Katayoun, Jin, Fang, AbouChehade, Jackson E., Hansen, Michael J., Iezzi, Raymond, Pavelko, Kevin D., Johnson, Aaron J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124655/
https://www.ncbi.nlm.nih.gov/pubmed/30211113
http://dx.doi.org/10.3389/fonc.2018.00320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124655/
https://www.ncbi.nlm.nih.gov/pubmed/30211113
http://dx.doi.org/10.3389/fonc.2018.00320

Ejemplares similares